1374P Radiographic progression-free survival correlation with time-to-event endpoints: A post hoc analysis of the VISION trial

Morris, M.J.; Bono, Johann S. de; Nagarajah, J.; Wei, X.X.; Nordquist, Luke T.; Koshkin, V.S.; Vickers, A.; Mirante, Osvaldo; Ghouse, R.; Tagawa, Scott T.; Fizazi, Karim

doi:10.1016/j.annonc.2022.07.1506

Search citation statements

Order By: Relevance

Paper Sections

Select...

E5911

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another post-hoc analysis from the VISION trial examined the correlation between several endpoints and the eventual survival endpoint. 22 There was a moderate-to-strong correlation between rPFS and OS, suggesting that rPFS may be relevant as an early endpoint for regulatory approval and clinical trial design in mCRPC patients undergoing radioligand therapy. The RALU study demonstrated that 177 Lu-PSMA therapy in patients previously treated with radium-223 (Ra223) had an acceptable safety profile and effectiveness in terms of OS and rPFS, and was similar to other findings with 177 Lu-PSMA, indicating no cross-resistance.…”

Section: E591mentioning

confidence: 91%